UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1123-13
Program Prior Authorization/Notification
Medication Valchlor® gel for topical use (mechlorethamine)
P&T Approval Date 4/2014, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020,
10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Valchlor gel for topical use (mechlorethamine) is an alkylating drug indicated for the topical
treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients
who have received prior skin-directed therapy.1 The National Cancer Comprehensive Network
(NCCN) recommends use of topical mechlorethamine in T-cell leukemia/lymphoma, primary
cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders,
and Langerhans Cell Histiocytosis (LCH).2
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Valchlor will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Primary Cutaneous Lymphomas
1. Initial Authorization
a. Valchlor will be approved based on the following criteria:
(1) Diagnosis of one of the following:
(a) Chronic or smoldering T-cell leukemia/lymphoma
(b) Primary cutaneous marginal zone or follicle center B-cell lymphoma
(c) Lymphomatoid papulosis (LyP) with extensive lesions
(d) Mycosis fungoides (MF)/Sezary syndrome (SS)
© 2024 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
2. Reauthorization
a. Valchlor will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Valchlor
Authorization will be issued for 12 months.
C. Histiocytic Neoplasms
1. Initial Authorization
a. Valchlor will be approved based on both of the following criteria:
(1) Diagnosis of Langerhans Cell Histiocytosis (LCH)
-AND–
(2) Skin disease is unifocal and isolated
Authorization will be issued for 12 months.
2. Reauthorization
a. Valchlor will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Valchlor
Authorization will be issued for 12 months.
D. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
© 2024 UnitedHealthcare Services, Inc.
2
and/or claim logic. Use of automated approval and re-approval processes varies by
program.
• Supply limits may be in place.
4. References:
1. Valchlor [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.;
January 2020.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia.
Accessed September 11, 2024.
Program Prior Authorization/Notification - Valchlor gel for topical use
(mechlorethamine)
Change Control
4/2014 New criteria.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
11/2014 Annual review. Updated references.
11/2015 Annual review. Added additional NHL indications to coverage criteria
and updated MF/SS criteria. Updated background & references.
9/2016 Annual review. Updated references.
9/2017 Annual review. Updated criteria for mycosis fungoides/sezary
syndrome. Updated references.
9/2018 Annual review. Updated criteria based on NCCN Compendium.
Updated references.
9/2019 Annual review. Renamed NHL to Primary Cutaneous Lymphomas.
Revised coverage rationale based on NCCN Compendium. Updated
references. Added general NCCN recommended review criteria.
9/2020 Annual review. No changes to coverage criteria.
10/2021 Annual review. Added coverage rationale for LCH according to NCCN
Compendium. Updated references.
10/2022 Annual review. No changes to coverage criteria. Added state mandate.
Updated references.
10/2023 Annual review. No changes to coverage criteria. Updated references.
10/2024 Annual review. No changes to coverage criteria. Updated references.
© 2024 UnitedHealthcare Services, Inc.
3